5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | BUY | BUY | BUY | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.49▲ | 3.55▼ | 3.62▼ | 3.21▲ | 3.05▲ |
MA10 | 3.62▼ | 3.64▼ | 3.50▲ | 2.98▲ | 4.05▼ |
MA20 | 3.63▼ | 3.43▲ | 3.29▲ | 2.95▲ | 4.28▼ |
MA50 | 3.30▲ | 3.15▲ | 3.06▲ | 4.22▼ | 3.85▼ |
MA100 | 3.13▲ | 2.85▲ | 2.94▲ | 4.32▼ | 6.17▼ |
MA200 | 2.80▲ | 3.17▲ | 3.84▼ | 3.70▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.047▼ | -0.016▼ | 0.019▲ | 0.150▲ | -0.198▼ |
RSI | 51.545▲ | 56.987▲ | 59.994▲ | 51.991▲ | 46.958▼ |
STOCH | 9.397▼ | 42.638 | 69.295 | 65.687 | 23.199 |
WILL %R | -78.723▼ | -52.113 | -44.048 | -18.500▲ | -69.998 |
CCI | -63.325 | -12.048 | 36.167 | 134.861▲ | -71.314 |
Wednesday, May 15, 2024 05:17 AM
Q1 2024 Earnings Call Transcript May 14, 2024 Operator: Good afternoon, everyone. And welcome to the NRx Pharmaceuticals, Inc. First Quarter of 2024 Results Conference Call [Operator Instructions]. As ...
|
Wednesday, May 15, 2024 01:03 AM
Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional investor ...
|
Wednesday, May 15, 2024 12:13 AM
Significant financial improvements and advances in clinical trials mark NRX Pharmaceuticals Inc's first quarter of 2024.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/05/24 | 3.62 | 3.90 | 3.41 | 3.53 | 910,072 |
15/05/24 | 3.23 | 3.25 | 3.02 | 3.23 | 182,108 |
14/05/24 | 3.01 | 3.29 | 2.931 | 3.18 | 271,403 |
13/05/24 | 2.88 | 3.07 | 2.88 | 3.07 | 144,779 |
10/05/24 | 2.93 | 3.19 | 2.90 | 3.04 | 361,172 |
09/05/24 | 2.80 | 3.10 | 2.74 | 2.93 | 590,434 |
08/05/24 | 2.83 | 2.99 | 2.674 | 2.82 | 399,808 |
07/05/24 | 3.06 | 3.23 | 2.74 | 2.81 | 1,069,439 |
06/05/24 | 2.32 | 3.75 | 2.32 | 3.06 | 9,310,734 |
03/05/24 | 2.13 | 2.44 | 2.01 | 2.10 | 268,096 |
|
|
||||
|
|
||||
|
|